Global Iohexol Injection 麻豆原创 Research Report 2023

Publication ID:

PB504231083

Publication Date:

May 12, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Highlights
The global Iohexol Injection market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Iohexol Injection is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Iohexol Injection is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Iohexol Injection include GE Healthcare, Imax, Grupo Juste, Daiichi Sankyo, Takeda, Fuji Pharma, Towaseiyaku, Hikari Pharmaceutical and YRPG, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Iohexol Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Iohexol Injection.
The Iohexol Injection market size, estimations, and forecasts are provided in terms of sales volume (K L) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Iohexol Injection market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Iohexol Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
GE Healthcare
Imax
Grupo Juste
Daiichi Sankyo
Takeda
Fuji Pharma
Towaseiyaku
Hikari Pharmaceutical
YRPG
BeiLu Pharma
Segment by Type
350mg I/ml
240mg I/ml
300mg I/ml
Others
Segment by Application
Hospitals
Clinics
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Iohexol Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Iohexol Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Iohexol Injection 麻豆原创 Overview
1.1 Product Overview and Scope of Iohexol Injection
1.2 Iohexol Injection Segment by Type
1.2.1 Global Iohexol Injection 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 350mg I/ml
1.2.3 240mg I/ml
1.2.4 300mg I/ml
1.2.5 Others
1.3 Iohexol Injection Segment by Application
1.3.1 Global Iohexol Injection 麻豆原创 Value by Application: (2023-2029)
1.3.2 Hospitals
1.3.3 Clinics
1.4 Global Iohexol Injection 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Iohexol Injection Revenue 2018-2029
1.4.2 Global Iohexol Injection Sales 2018-2029
1.4.3 Global Iohexol Injection 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Iohexol Injection 麻豆原创 Competition by Manufacturers
2.1 Global Iohexol Injection Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Iohexol Injection Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Iohexol Injection Average Price by Manufacturers (2018-2023)
2.4 Global Iohexol Injection Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Iohexol Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Iohexol Injection, Product Type & Application
2.7 Iohexol Injection 麻豆原创 Competitive Situation and Trends
2.7.1 Iohexol Injection 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Iohexol Injection Players 麻豆原创 Share by Revenue
2.7.3 Global Iohexol Injection 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Iohexol Injection Retrospective 麻豆原创 Scenario by Region
3.1 Global Iohexol Injection 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Iohexol Injection Global Iohexol Injection Sales by Region: 2018-2029
3.2.1 Global Iohexol Injection Sales by Region: 2018-2023
3.2.2 Global Iohexol Injection Sales by Region: 2024-2029
3.3 Global Iohexol Injection Global Iohexol Injection Revenue by Region: 2018-2029
3.3.1 Global Iohexol Injection Revenue by Region: 2018-2023
3.3.2 Global Iohexol Injection Revenue by Region: 2024-2029
3.4 North America Iohexol Injection 麻豆原创 Facts & Figures by Country
3.4.1 North America Iohexol Injection 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Iohexol Injection Sales by Country (2018-2029)
3.4.3 North America Iohexol Injection Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Iohexol Injection 麻豆原创 Facts & Figures by Country
3.5.1 Europe Iohexol Injection 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Iohexol Injection Sales by Country (2018-2029)
3.5.3 Europe Iohexol Injection Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Iohexol Injection 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Iohexol Injection 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Iohexol Injection Sales by Country (2018-2029)
3.6.3 Asia Pacific Iohexol Injection Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Iohexol Injection 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Iohexol Injection 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Iohexol Injection Sales by Country (2018-2029)
3.7.3 Latin America Iohexol Injection Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Iohexol Injection 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Iohexol Injection 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Iohexol Injection Sales by Country (2018-2029)
3.8.3 Middle East and Africa Iohexol Injection Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Iohexol Injection Sales by Type (2018-2029)
4.1.1 Global Iohexol Injection Sales by Type (2018-2023)
4.1.2 Global Iohexol Injection Sales by Type (2024-2029)
4.1.3 Global Iohexol Injection Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Iohexol Injection Revenue by Type (2018-2029)
4.2.1 Global Iohexol Injection Revenue by Type (2018-2023)
4.2.2 Global Iohexol Injection Revenue by Type (2024-2029)
4.2.3 Global Iohexol Injection Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Iohexol Injection Price by Type (2018-2029)
5 Segment by Application
5.1 Global Iohexol Injection Sales by Application (2018-2029)
5.1.1 Global Iohexol Injection Sales by Application (2018-2023)
5.1.2 Global Iohexol Injection Sales by Application (2024-2029)
5.1.3 Global Iohexol Injection Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Iohexol Injection Revenue by Application (2018-2029)
5.2.1 Global Iohexol Injection Revenue by Application (2018-2023)
5.2.2 Global Iohexol Injection Revenue by Application (2024-2029)
5.2.3 Global Iohexol Injection Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Iohexol Injection Price by Application (2018-2029)
6 Key Companies Profiled
6.1 GE Healthcare
6.1.1 GE Healthcare Corporation Information
6.1.2 GE Healthcare Description and Business Overview
6.1.3 GE Healthcare Iohexol Injection Sales, Revenue and Gross Margin (2018-2023)
6.1.4 GE Healthcare Iohexol Injection Product Portfolio
6.1.5 GE Healthcare Recent Developments/Updates
6.2 Imax
6.2.1 Imax Corporation Information
6.2.2 Imax Description and Business Overview
6.2.3 Imax Iohexol Injection Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Imax Iohexol Injection Product Portfolio
6.2.5 Imax Recent Developments/Updates
6.3 Grupo Juste
6.3.1 Grupo Juste Corporation Information
6.3.2 Grupo Juste Description and Business Overview
6.3.3 Grupo Juste Iohexol Injection Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Grupo Juste Iohexol Injection Product Portfolio
6.3.5 Grupo Juste Recent Developments/Updates
6.4 Daiichi Sankyo
6.4.1 Daiichi Sankyo Corporation Information
6.4.2 Daiichi Sankyo Description and Business Overview
6.4.3 Daiichi Sankyo Iohexol Injection Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Daiichi Sankyo Iohexol Injection Product Portfolio
6.4.5 Daiichi Sankyo Recent Developments/Updates
6.5 Takeda
6.5.1 Takeda Corporation Information
6.5.2 Takeda Description and Business Overview
6.5.3 Takeda Iohexol Injection Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Takeda Iohexol Injection Product Portfolio
6.5.5 Takeda Recent Developments/Updates
6.6 Fuji Pharma
6.6.1 Fuji Pharma Corporation Information
6.6.2 Fuji Pharma Description and Business Overview
6.6.3 Fuji Pharma Iohexol Injection Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Fuji Pharma Iohexol Injection Product Portfolio
6.6.5 Fuji Pharma Recent Developments/Updates
6.7 Towaseiyaku
6.6.1 Towaseiyaku Corporation Information
6.6.2 Towaseiyaku Description and Business Overview
6.6.3 Towaseiyaku Iohexol Injection Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Towaseiyaku Iohexol Injection Product Portfolio
6.7.5 Towaseiyaku Recent Developments/Updates
6.8 Hikari Pharmaceutical
6.8.1 Hikari Pharmaceutical Corporation Information
6.8.2 Hikari Pharmaceutical Description and Business Overview
6.8.3 Hikari Pharmaceutical Iohexol Injection Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Hikari Pharmaceutical Iohexol Injection Product Portfolio
6.8.5 Hikari Pharmaceutical Recent Developments/Updates
6.9 YRPG
6.9.1 YRPG Corporation Information
6.9.2 YRPG Description and Business Overview
6.9.3 YRPG Iohexol Injection Sales, Revenue and Gross Margin (2018-2023)
6.9.4 YRPG Iohexol Injection Product Portfolio
6.9.5 YRPG Recent Developments/Updates
6.10 BeiLu Pharma
6.10.1 BeiLu Pharma Corporation Information
6.10.2 BeiLu Pharma Description and Business Overview
6.10.3 BeiLu Pharma Iohexol Injection Sales, Revenue and Gross Margin (2018-2023)
6.10.4 BeiLu Pharma Iohexol Injection Product Portfolio
6.10.5 BeiLu Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Iohexol Injection Industry Chain Analysis
7.2 Iohexol Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Iohexol Injection Production Mode & Process
7.4 Iohexol Injection Sales and 麻豆原创ing
7.4.1 Iohexol Injection Sales Channels
7.4.2 Iohexol Injection Distributors
7.5 Iohexol Injection Customers
8 Iohexol Injection 麻豆原创 Dynamics
8.1 Iohexol Injection Industry Trends
8.2 Iohexol Injection 麻豆原创 Drivers
8.3 Iohexol Injection 麻豆原创 Challenges
8.4 Iohexol Injection 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

GE Healthcare
Imax
Grupo Juste
Daiichi Sankyo
Takeda
Fuji Pharma
Towaseiyaku
Hikari Pharmaceutical
YRPG
BeiLu Pharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.